Thrombolysis for Minor Stroke: The Critical Distinction Between Disabling and Non-Disabling Deficits

Minor strokes—typically defined as NIHSS ≤5—account for a substantial proportion of acute ischemic stroke presentations. For years, clinicians debated whether these patients benefit from intravenous thrombolysis, weighing the potential for neurological recovery against bleeding risk. Recent trials have provided clarity, but their interpretation requires understanding a critical distinction: minor and disabling versus minor and non-disabling strokes. The trials that showed no benefit from thrombolysis specifically enrolled patients with non-disabling symptoms—a population fundamentally different from those with low NIHSS but functionally significant deficits.

Updated to reflect the 2026 AHA/ASA Guidelines for Early Management of Acute Ischemic Stroke.

Defining "Disabling" in Minor Stroke

The NIHSS, while useful for standardized assessment, does not capture functional impact. A patient with isolated hand weakness (NIHSS 1–2) who is a surgeon or musician has a profoundly disabling stroke. Conversely, a patient with mild facial droop and dysarthria (NIHSS 2) may have minimal functional limitation.

Examples of disabling deficits regardless of NIHSS score:

• Visual field cut (hemianopia): Prevents driving, impacts safety and independence
• Aphasia: Even mild word-finding difficulty can be devastating for communication
• Hand or grip weakness: Affects fine motor tasks, writing, work capacity
• Significant ataxia: Impairs gait, balance, and fall risk
• Neglect: Impacts spatial awareness and safety
• Lower extremity weakness: Affects ambulation and independence

Examples of non-disabling deficits (per 2026 guidelines):

• Isolated sensory symptoms
• Isolated mild ataxia
• Isolated facial weakness
• Isolated dysarthria
• Mild isolated limb weakness without functional impact

The key question is not "What is the NIHSS?" but rather "Will this patient return to their baseline function without treatment?"

The Trials: All Enrolled Non-Disabling Strokes

Three major trials have evaluated thrombolysis in minor stroke. Critically, all three specifically excluded or did not target patients with disabling symptoms.

PRISMS (2018)

PRISMS randomized 313 patients with NIHSS 0–5 and deficits "judged not clearly disabling" to IV alteplase versus aspirin within 3 hours of onset.

• mRS 0–1 at 90 days: 78.2% (alteplase) vs. 81.5% (aspirin)
• Adjusted risk difference: −1.1% (95% CI −9.4% to 7.3%)
• Symptomatic ICH: 3.2% (alteplase) vs. 0% (aspirin)
• Trial stopped early for futility after slow enrollment

Key Inclusion Criterion: "Deficits judged not clearly disabling" — patients with disabling symptoms were excluded.

2026 Guideline Impact: PRISMS is cited as the basis for the Class 3: No Benefit recommendation for non-disabling minor stroke.

ARAMIS (2023)

ARAMIS compared dual antiplatelet therapy (DAPT: aspirin + clopidogrel) to IV alteplase in patients with minor, non-disabling acute ischemic stroke in China.

• mRS 0–1 at 90 days: 93.8% (DAPT) vs. 91.4% (alteplase)
• Risk difference: 2.3% (95% CI −1.5% to 6.2%); P<0.001 for non-inferiority
• Symptomatic ICH: 0.3% (DAPT) vs. 0.9% (alteplase)
• Any bleeding: 1.6% vs. 5.4% (P=0.006)

Key Finding: In minor non-disabling stroke, DAPT was non-inferior to alteplase with significantly less bleeding. However, over 90% of both groups achieved excellent outcomes—reflecting the favorable natural history of non-disabling minor stroke.

TEMPO-2 (2024)

TEMPO-2 evaluated IV tenecteplase versus standard care (primarily DAPT) in patients with minor stroke (NIHSS ≤5) and confirmed intracranial occlusion or perfusion abnormality within 12 hours.

• Return to baseline mRS: 71.5% (tenecteplase) vs. 74.8% (standard care)
• Risk ratio: 0.96 (95% CI 0.88–1.04; P=0.29)
• Symptomatic ICH: 1.9% vs. 0.4%
• 90-day mortality: 4.6% (tenecteplase) vs. 1.1% (standard care); adjusted HR 3.8; P=0.009
• Trial stopped early for futility

Key Finding: Even in minor stroke patients with documented intracranial occlusion, thrombolysis did not improve outcomes and was associated with significantly higher mortality. The trial reinforces that low NIHSS with occlusion does not automatically warrant thrombolysis if symptoms are non-disabling.

Why These Trials Don't Apply to Disabling Minor Strokes

Trial Design Excluded Disabling Symptoms

All three trials explicitly enrolled patients with non-disabling deficits. PRISMS required symptoms "not clearly disabling." ARAMIS targeted "minor non-disabling" strokes. TEMPO-2 enrolled low NIHSS patients where the natural history was expected to be favorable. Patients with hemianopia, aphasia, or functionally significant weakness—even with NIHSS ≤5—were not the target population.

Favorable Natural History in Control Arms

The control groups in these trials had excellent outcomes: 74–82% achieved mRS 0–1 without thrombolysis. This reflects the benign natural history of truly non-disabling minor stroke. In contrast, patients with disabling deficits have more to lose from untreated stroke and more to gain from reperfusion.

No Evidence to Withhold Treatment in Disabling Stroke

There is no randomized trial evidence supporting withholding thrombolysis from patients with minor but disabling symptoms. The foundational tPA trials (NINDS, ECASS III) did not exclude low NIHSS patients with disabling deficits. Extrapolating from non-disabling minor stroke trials to withhold treatment from a patient with isolated hand weakness or hemianopia is not evidence-based.

Clinical Approach to Minor Stroke

Step 1: Assess Disability, Not Just NIHSS

Ask: "If this deficit persists, will it significantly impact the patient's function, independence, or livelihood?" Consider occupation, baseline activities, and patient goals.

Step 2: For Non-Disabling Symptoms

Based on PRISMS, ARAMIS, and TEMPO-2, and now endorsed by 2026 guidelines (Class 3: No Benefit), dual antiplatelet therapy is preferred over thrombolysis. Excellent outcomes (~90%) are expected regardless of treatment choice, and bleeding risk is lower without thrombolysis.

Step 3: For Disabling Symptoms

Treat with IV thrombolysis per 2026 guidelines (Class 2a). The minor stroke trials do not provide evidence to withhold treatment from patients whose deficits—though numerically low on NIHSS—would meaningfully impact their quality of life if permanent.

Conclusion

The 2026 guidelines provide formal clarity on an issue that has long challenged stroke clinicians. For truly non-disabling symptoms, antiplatelet therapy achieves equivalent outcomes with less bleeding risk (Class 3: No Benefit for IVT). However, for minor but disabling strokes, IVT remains reasonable (Class 2a). The NIHSS is a blunt instrument that fails to capture disability. A low score does not mean low stakes. The critical question remains: "Will this deficit matter to this patient?"

Trial Comparison Table